Equities

Arecor Therapeutics PLC

Arecor Therapeutics PLC

Actions
  • Price (EUR)0.885
  • Today's Change0.02 / 2.31%
  • Shares traded3.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 15:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6.751318
Total Receivables, Net3.322.821.57
Total Inventory0.771.13--
Prepaid expenses0.320.720.63
Other current assets, total------
Total current assets111721
Property, plant & equipment, net0.830.840.33
Goodwill, net1.481.48--
Intangibles, net1.811.920.03
Long term investments------
Note receivable - long term0.080.050.05
Other long term assets------
Total assets152221
LIABILITIES
Accounts payable2.251.710.52
Accrued expenses2.231.391.25
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.120.200.13
Other current liabilities, total0.550.420.37
Total current liabilities5.153.732.27
Total long term debt0.220.090.11
Total debt0.340.290.23
Deferred income tax0.450.50--
Minority interest------
Other liabilities, total0.03--0
Total liabilities5.854.312.37
SHAREHOLDERS EQUITY
Common stock0.310.310.28
Additional paid-in capital292923
Retained earnings (accumulated deficit)(31)(23)(17)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total111111
Total equity9.531719
Total liabilities & shareholders' equity152221
Total common shares outstanding313128
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.